{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:36Z","timestamp":1786980216189,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Tissue Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00441-018-2906-y","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T22:58:40Z","timestamp":1536015520000},"page":"577-585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The BET bromodomain inhibitor i-BET151 impairs ovarian cancer metastasis and improves antitumor immunity"],"prefix":"10.1007","volume":"374","author":[{"given":"Ai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianxia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"2906_CR1","doi-asserted-by":"crossref","unstructured":"Aird F, Kandela I, Mantis C, Reproducibility Project: Cancer B (2017) Replication study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Elife 6","DOI":"10.7554\/eLife.21253"},{"key":"2906_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast Jr","year":"2009","unstructured":"Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415\u2013428","journal-title":"Nat Rev Cancer"},{"key":"2906_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15:49\u201363","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2906_CR4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146:904\u2013917","journal-title":"Cell"},{"key":"2906_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40471-017-0115-y","volume":"4","author":"JA Doherty","year":"2017","unstructured":"Doherty JA, Peres LC, Wang C, Way GP, Greene CS, Schildkraut JM (2017) Challenges and opportunities in studying the epidemiology of ovarian Cancer subtypes. Curr Epidemiol Rep 4:211\u2013220","journal-title":"Curr Epidemiol Rep"},{"key":"2906_CR6","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","volume":"28","author":"DB Doroshow","year":"2017","unstructured":"Doroshow DB, Eder JP, LoRusso PM (2017) BET inhibitors: a novel epigenetic approach. Ann Oncol 28:1776\u20131787","journal-title":"Ann Oncol"},{"key":"2906_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.pbiomolbio.2011.03.007","volume":"106","author":"H Enderling","year":"2011","unstructured":"Enderling H, Hahnfeldt P (2011) Cancer stem cells in solid tumors: is \u2018evading apoptosis\u2019 a hallmark of cancer? Prog Biophys Mol Biol 106:391\u2013399","journal-title":"Prog Biophys Mol Biol"},{"key":"2906_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.tcb.2013.07.006","volume":"23","author":"K Fernald","year":"2013","unstructured":"Fernald K, Kurokawa M (2013) Evading apoptosis in cancer. Trends Cell Biol 23:620\u2013633","journal-title":"Trends Cell Biol"},{"key":"2906_CR9","doi-asserted-by":"crossref","first-page":"17532","DOI":"10.18632\/oncotarget.3947","volume":"6","author":"B Han","year":"2015","unstructured":"Han B, Yao W, Oh YT, Tong JS, Li S, Deng J, Yue P, Khuri FR, Sun SY (2015) The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5. Oncotarget 6:17532\u201317542","journal-title":"Oncotarget"},{"key":"2906_CR10","doi-asserted-by":"crossref","unstructured":"Hu J, Zhang L, Chen Q, Lin J, Wang S, Liu R, Zhang W, Miao K, Shou T (2017) Knockdown of CPEB4 expssion suppresses cell migration and invasion via Akt pathway in non-small cell lung cancer. Cell Biol Int","DOI":"10.1002\/cbin.10930"},{"key":"2906_CR11","doi-asserted-by":"publisher","first-page":"e07072","DOI":"10.7554\/eLife.07072","volume":"4","author":"I Kandela","year":"2015","unstructured":"Kandela I, Jin HY, Owen K, Reproducibility Project: Cancer B (2015) Registered report: BET bromodomain inhibitionre as a therapeutic strategy to target c-Myc. Elife 4:e07072","journal-title":"Elife"},{"key":"2906_CR12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00404-017-4529-z","volume":"296","author":"DM Klotz","year":"2017","unstructured":"Klotz DM, Wimberger P (2017) Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube? Arch Gynecol Obstet 296:1055\u20131062","journal-title":"Arch Gynecol Obstet"},{"key":"2906_CR13","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.4161\/15384047.2014.962297","volume":"15","author":"SE Lochrin","year":"2014","unstructured":"Lochrin SE, Price DK, Figg WD (2014) BET bromodomain inhibitors\u2014a novel epigenetic approach in castration-resistant prostate cancer. Cancer Biol Ther 15:1583\u20131585","journal-title":"Cancer Biol Ther"},{"key":"2906_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.cell.2012.06.045","volume":"150","author":"MM Matzuk","year":"2012","unstructured":"Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S, Bradner JE (2012) Small-molecule inhibition of BRDT for male contraception. Cell 150:673\u2013684","journal-title":"Cell"},{"key":"2906_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2184.2012.00845.x","volume":"45","author":"L Ouyang","year":"2012","unstructured":"Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, Bao JK (2012) Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif 45:487\u2013498","journal-title":"Cell Prolif"},{"key":"2906_CR16","doi-asserted-by":"crossref","first-page":"97657","DOI":"10.18632\/oncotarget.18280","volume":"8","author":"Z Pan","year":"2017","unstructured":"Pan Z, Xie X (2017) BRCA mutations in the manifestation and treatment of ovarian cancer. Oncotarget 8:97657\u201397670","journal-title":"Oncotarget"},{"key":"2906_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","volume":"3","author":"A Puissant","year":"2013","unstructured":"Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier K (2013) Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 3:308\u2013323","journal-title":"Cancer Discov"},{"key":"2906_CR18","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/s41467-017-02390-7","volume":"8","author":"R Qi","year":"2017","unstructured":"Qi R, Wang Y, Bruno PM, Xiao H, Yingjie Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP (2017) Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun 8:2166","journal-title":"Nat Commun"},{"key":"2906_CR19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423\u20131437","journal-title":"Nat Med"},{"key":"2906_CR20","doi-asserted-by":"publisher","first-page":"x118","DOI":"10.1093\/annonc\/mds315","volume":"23","author":"FA Raja","year":"2012","unstructured":"Raja FA, Chopra N, Ledermann JA (2012) Optimal first-line treatment in ovarian cancer. Ann Oncol 23:x118\u2013x127","journal-title":"Ann Oncol"},{"key":"2906_CR21","doi-asserted-by":"crossref","first-page":"104687","DOI":"10.18632\/oncotarget.22191","volume":"8","author":"S Sharma","year":"2017","unstructured":"Sharma S, Zuniga F, Rice GE, Perrin LC, Hooper JD, Salomon C (2017) Tumor-derived exosomes in ovarian cancer\u2014liquid biopsies for early detection and real-time monitoring of cancer progression. Oncotarget 8:104687\u2013104703","journal-title":"Oncotarget"},{"key":"2906_CR22","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1158\/1535-7163.MCT-17-0032","volume":"16","author":"J Tong","year":"2017","unstructured":"Tong J, Tan S, Nikolovska-Coleska Z, Yu J, Zou F, Zhang L (2017a) FBW7-dependent Mcl-1 degradation mediates the anticancer effect of Hsp90 inhibitors. Mol Cancer Ther 16:1979\u20131988","journal-title":"Mol Cancer Ther"},{"key":"2906_CR23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/onc.2016.247","volume":"36","author":"J Tong","year":"2017","unstructured":"Tong J, Tan S, Zou F, Yu J, Zhang L (2017b) FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene 36:787\u2013796","journal-title":"Oncogene"},{"key":"2906_CR24","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/0008-5472.CAN-16-3242","volume":"77","author":"J Tong","year":"2017","unstructured":"Tong J, Wang P, Tan S, Chen D, Nikolovska-Coleska Z, Zou F, Yu J, Zhang L (2017c) Mcl-1 degradation is required for targeted therapeutics to eradicate Colon cancer cells. Cancer Res 77:2512\u20132521","journal-title":"Cancer Res"},{"key":"2906_CR25","first-page":"e620","volume":"8","author":"E Wadhwa","year":"2016","unstructured":"Wadhwa E, Nicolaides T (2016) Bromodomain inhibitor review: bromodomain and extra-terminal family protein inhibitors as a potential new therapy in central nervous system tumors. Cureus 8:e620","journal-title":"Cureus"},{"key":"2906_CR26","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3892\/ol.2017.6388","volume":"14","author":"X Xie","year":"2017","unstructured":"Xie X, Yang M, Ding Y, Chen J (2017) Microbial infection, inflammation and epithelial ovarian cancer. Oncol Lett 14:1911\u20131919","journal-title":"Oncol Lett"},{"key":"2906_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.critrevonc.2016.03.015","volume":"102","author":"W Xu","year":"2016","unstructured":"Xu W, Rush J, Rickett K, Coward JI (2016) Mucinous ovarian cancer: a therapeutic review. Crit Rev Oncol Hematol 102:26\u201336","journal-title":"Crit Rev Oncol Hematol"},{"key":"2906_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biocel.2017.12.010","volume":"95","author":"XY Zhang","year":"2017","unstructured":"Zhang XY, Zhang M, Cong Q, Zhang MX, Zhang MY, Lu YY, Xu CJ (2017) Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy. Int J Biochem Cell Biol 95:9\u201316","journal-title":"Int J Biochem Cell Biol"}],"container-title":["Cell and Tissue Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00441-018-2906-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-018-2906-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-018-2906-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T16:14:20Z","timestamp":1604852060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00441-018-2906-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2906"],"URL":"https:\/\/doi.org\/10.1007\/s00441-018-2906-y","relation":{},"ISSN":["0302-766X","1432-0878"],"issn-type":[{"value":"0302-766X","type":"print"},{"value":"1432-0878","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"assertion":[{"value":"3 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement on the welfare of animals"}}]}}